Microbot Medical Inc. Files 8-K: Material Agreement & Equity Sales

TL;DR

Microbot Medical (MBOT) filed an 8-K detailing a material agreement and equity sales. Keep an eye on this.

AI Summary

Microbot Medical Inc. announced on September 14, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. The filing includes financial statements and exhibits.

Why It Matters

This 8-K filing indicates significant corporate activity for Microbot Medical Inc., including a new material agreement and equity transactions, which could impact its financial standing and future operations.

Risk Assessment

Risk Level: medium — The filing involves material definitive agreements and unregistered equity sales, which can introduce financial and operational risks.

Key Players & Entities

• Microbot Medical Inc. (company) — Registrant
• September 14, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 000-19871 (legal_document_id) — SEC File Number
• 94-3078125 (tax_id) — IRS Employer Identification No.

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value MBOT NASDAQ Capital Mark
• $1.50 — Stock, at exercise prices ranging from $1.50 to $2.13 per share, in consideration fo
• $2.13 — t exercise prices ranging from $1.50 to $2.13 per share, in consideration for the Com
• $4.50 — ew PIO Shares") at an exercise price of $4.50 per share (collectively, the "Inducemen
• $2.10 — Stock for cash at an exercise price of $2.10 per share and will receive New PIOs to
• $25.2 million — eceived gross proceeds of approximately $25.2 million from the exercise of certain Existing P
• $4.0 million — receive gross proceeds of approximately $4.0 million from the exercise of certain Existing P
• $25,000 — Offerings, a non-accountable expense of $25,000, up to $35,000 for its fees and expense
• $35,000 — n-accountable expense of $25,000, up to $35,000 for its fees and expenses of legal coun
• $15,950 — fees and expenses of legal counsel and $15,950 for clearing expenses. The Company has
• $1.875 — of Common Stock at an exercise price of $1.875 (ii) 31,429 shares of Common Stock at a
• $2 — of Common Stock at an exercise price of $2.1875, (iii) 138,906 shares of Common St
• $2.625 — of Common Stock at an exercise price of $2.625 and (iv) 422,535 shares of Common Stock
• $1 — er 16, 2030 and at an exercise price of $1.875, (ii) preferred investment options
• $2.6625 — er 16, 2027 and at an exercise price of $2.6625 (collectively, the "Additional Wainwrig

Filing Documents

• form8-k.htm (8-K) — 65KB
• ex4-1.htm (EX-4.1) — 136KB
• ex4-2.htm (EX-4.2) — 139KB
• ex10-1.htm (EX-10.1) — 63KB
• ex99-1.htm (EX-99.1) — 16KB
• ex99-2.htm (EX-99.2) — 16KB
• 0001493152-25-013743.txt ( ) — 688KB
• mbot-20250914.xsd (EX-101.SCH) — 3KB
• mbot-20250914_lab.xml (EX-101.LAB) — 33KB
• mbot-20250914_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. MICROBOT MEDICAL INC. By: /s/ Harel Gadot Name: Harel Gadot Title: Chief Executive Officer, President and Chairman Date: September 16, 2025

View Full Filing

View this 8-K filing on SEC EDGAR